Rumboldt Zoran, Rowley Howard A, Steinberg Fred, Maldjian Joseph A, Ruscalleda Jordi, Gustafsson Lars, Bastianello Stefano
Medical University of South Carolina, Department of Radiology, Charleston, SC, USA.
J Magn Reson Imaging. 2009 Apr;29(4):760-7. doi: 10.1002/jmri.21695.
To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T).
Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (kappa) statistics.
There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (kappa = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2%), CNR (+51.3-147.6%), and % lesion enhancement (+45.9-49.5%) was noted with gadobenate dimeglumine.
Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.
前瞻性比较0.1 mmol/kg剂量的钆贝葡胺和钆喷酸葡胺用于3特斯拉（T）脑病变对比增强磁共振成像（MRI）的效果。
46例随机分组的患者先接受一次使用钆贝葡胺（n = 23）或钆喷酸葡胺（n = 23）的检查，然后在2 - 7天后接受另一种造影剂的第二次检查。每位患者两次检查的造影剂给药（剂量、速率）、序列参数（T1加权自旋回波序列；T1加权梯度回波序列）以及注射造影剂与图像采集之间的间隔均相同。三位不知情的神经放射科医生对图像进行定性（病变描绘、病变强化、总体偏好）和定量（病变与脑比值[LBR]、对比噪声比[CNR]、病变强化百分比）评估。采用Wilcoxon符号秩检验评估差异。使用kappa统计量确定阅片者之间的一致性。
两组患者在人口统计学方面无差异。三位阅片者分别在22例（53.7%）、21例（51.2%）和27例（65.9%）患者中总体上更倾向于钆贝葡胺，而对于钆喷酸葡胺，分别为0例、1例和0例。在病变边界描绘和强化方面也表现出类似的显著（P < 0.001）偏好。阅片者之间的一致性始终良好（kappa = 0.48 - 0.64）。使用钆贝葡胺时，LBR（升高43.5% - 61.2%）、CNR（升高51.3% - 147.6%）和病变强化百分比（升高45.9% - 49.5%）均显著（P < 0.05）更高。
0.1 mmol/kg钆贝葡胺显著改善了3T时脑病变的显示。
